This 2016 video by Dr. Teirstein Pres of @InfoNbpas would B the BEST 15 mins of UR time today.
Just pls watch. Paul will appear on #HealthcareUnfiltered soon to discuss more & provide a path forward. @AaronGoodman33 @VincentRK@doctorwes CC @MorieGertz
https://t.co/D5lFZaTdjO
On ABIM MOC. Please read!!!
To maintain the trust of patients we need to test the testers who test doctors
@AaronGoodman33 @doctorwes@chadinabhan@DavidSteensma We must create a Board Exam to ensure that ABIM leaders are qualified Testers. Goal is to improve patient care.
1/
ABIM must wake up to the realization that doctors carry a smart phone computer with them. We work in teams. We have colleagues who we can consult for rare disorders and when doubts arise
End MOC. It’s useless.
CME, maintenance of licensure & credentialing is enough.
@mtmdphd@RahulBanerjeeMD So many questions come to mind
Is this of utility to follow in CAR..and what about changes in allo transplant patients …any interaction with the T cell subsets activity and changes in microbiome
Very interesting
@mtmdphd Ordered a copy! 30 dollars and ships in 6 weeks on Amazon prime
A Physician's Journey: The Memoir of Robert A. Kyle, M.D. https://t.co/v25nOeVcPC
@VincentRK
I want to hear from @ASH_hematology and @ASCO on what concrete things have been accomplished since your letters and surveys on ABIM MOC?
@AaronGoodman33 @chadinabhan#MedTwitter
250 citations! --> Assoc of Clinical Factors & Recent Anti-Cancer Therapy w/ COVID-19 Severity among Patients with Cancer: Report from COVID-19 & Cancer Consortium [3/18/21] @PGrivasMDPhD@arkhaki et al. @COVID19nCCC@Annals_Oncology https://t.co/WH5PPJySj6 #CCC19#COVID19nCancer
🎉Finally out🎉
Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B-cell lymphoma
The balance between improved efficacy, increased severe toxicity and resource utilization
Open access
@AnnaSureda5 #lymsm https://t.co/5b5NYGjO9d
Editorial @FDAOncology@NEJM#mmsm
✅22 cases out of 27,000, 14 with data
✅T-cell lymphoma,T-cell large granular lymphocytosis,peripheral T-cell lymphoma,cutaneous T-cell lymphoma
🛑3 cases with genetic info,CAR transgene detected in malignant clone
➡️https://t.co/6IR5Kg7nhH
#Myeloma Paper of the Day: Nice pre-clinical study shows bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth better than just targeting BCMA by enhancing macrophage phagocytic clearance of myeloma cells: https://t.co/0NgJMSPR68.